NASDAQ · RZLT
Rezolute, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for RZLT: Nov 5, 2026
Rezolute, Inc. Common Stock (NV) is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.18. The reported EPS for the same quarter last year was $-0.18.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.18 | $-0.16 | $-0.20 | 2 |
| Dec 2026 | $-0.16 | $-0.14 | $-0.17 | 2 |
| Mar 2027 | $-0.16 | $-0.14 | $-0.17 | 2 |
| Jun 2027 | $-0.15 | $-0.13 | $-0.17 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews · Zacks- Fintel · Oct 30, 2:28 AM EDTRezolute, Inc. Outlines Ersodetug Clinical Milestones and Reports $108 million in CashRezolute, Inc. released an updated corporate presentation outlining clinical milestones and commercial opportunities for its lead candidate, ersodetug, an antibody designed to treat refractory hypoglycemia caused by hyperinsulinism. The company reported having $108 million in cas
- RTTNews · Oct 15, 1:14 AM EDTRezolute Completes Enrollment In Phase 3 UpLIFT Study Of Ersodetug For Tumor Hyperinsulinism(RTTNews) – Rezolute, Inc. (RZLT) has completed enrollment in its Phase 3 upLIFT study evaluating ersodetug in tumor hyperinsulinism, a rare condition that can cause severe and persistent low blood sugar. The company expects topline results from the study in mid-December 2026.
- Fintel · Oct 6, 2:14 PM EDTCantor Fitzgerald Upgrades Rezolute to Overweight from NeutralFintel reports that on October 6, 2026, Cantor Fitzgerald upgraded their outlook for Rezolute (NASDAQCM:RZLT) (DB:6HV1) from Neutral to Overweight.Prior to this rating action, the stock closed at $4.33 on October 5, 2026. This latest close of $4.33 represents a price change of +3
- RTTNews · Oct 5, 7:45 AM EDTFDA Recommends Next Regulatory Step For Rezolute's Ersodetug;Stock Up(RTTNews) – Rezolute, Inc. (RZLT) said the FDA has recommended a Type B pre-BLA meeting with the company as a precursor to a potential Biologics License Application (BLA) submission for ersodetug for the treatment of hypoglycemia caused by congenital hyperinsulinism.
- RTTNews · Oct 5, 7:34 AM EDTRezolute Prepares For Potential BLA Filing Of Ersodetug In Congenital HI(RTTNews) – Rezolute, Inc. (RZLT) on Monday announced that the FDA recommended a Type B pre-BLA meeting as a precursor to submitting a BLA for ersodetug for the treatment of hypoglycemia due to congenital hyperinsulinism.
- Fintel · Oct 2, 11:05 AM EDTRezolute Consensus Price Target Increased by 18.70% to $9.28The average one-year price target for Rezolute (NASDAQCM:RZLT) (DB:6HV1) has been revised to $9.28 / share. This is an increase of 18.70% from the prior estimate of $7.82 dated September 11, 2026. These figures represent aggregate analyst targets compiled by Fintel and do not con
- Fintel · Sep 29, 10:25 AM EDTCraig-Hallum Upgrades Rezolute to Buy from HoldFintel reports that on September 29, 2026, Craig-Hallum upgraded their outlook for Rezolute (NASDAQCM:RZLT) (DB:6HV1) from Hold to Buy.Prior to this rating action, the stock closed at $4.18 on September 28, 2026. This latest close of $4.18 represents a one-week price change of +6
- RTTNews · Sep 25, 4:02 AM EDTRezolute Posts Narrower Loss In Q4; Expects Phase 3 Ersodetug Topline Data By 2026 End(RTTNews) – Rezolute, Inc. (RZLT) reported fourth-quarter and full-year fiscal 2026 financial results and provided an update on its clinical program.
- RTTNews · Jun 5, 10:26 AM EDTWeekly Buzz: PHG, KMDA Win FDA Nod; FULC Halts Pociredir; RMD Closes Noctrix Deal; NVS Paces In IgAN(RTTNews) – This week, the biotech sector saw a wave of regulatory approvals in the U.S., alongside study halts, strategic collaborations, acquisitions, deal closures, and encouraging data readouts. Positive clinical study data readouts spanned multiple therapeutic areas, inclu
- Zacks · Jun 4, 11:58 AM EDTRZLT Stock on the Move: What Sparks the 38% Jump in the Past Week?Rezolute rises 38% in a week after interim upLIFT data shows most tumor HI patients cut or eliminate IV glucose support.
- RTTNews · Jun 3, 10:38 PM EDTTop Biotech Gainers: ABVX, CING, DRTS, MMED…(RTTNews) – Today's gainers list includes ABIVAX, which recently announced positive ulcerative colitis trial results; Cingulate, which is working toward resubmission of a New Drug Application for an ADHD therapy; and Alpha Tau, following its joint partnership with Tolmar to bring
- RTTNews · Jun 2, 11:32 AM EDTRezolute Reports Positive Interim Data In Phase 3 UpLIFT Study For Ersodetug For Tumor HI(RTTNews) – Rezolute Inc. (RZLT), a late-stage company focused on ultra-rare diseases, announced positive interim results from its ongoing Phase 3 upLIFT study of Ersodetug in patients with tumor-related hyperinsulinism (HI).
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Rezolute, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.